Table 1. Summarised baseline characteristics.

Variable	All	Infliximab	Adalimumab
n	46	20	26
Females, n (%)	22 (48%)	10 (50%)	12 (46%)
Age, median (range)	38 (19–67)	39 (19–61)	36 (20–67)
Smokers, n (%)	15 (33%)	5 (25%)	10 (39%)
Ileal disease, n (%)	28 (61%)	11 (55%)	17 (65%)
Colonic disease, n (%)	40 (87%)	17 (85%)	23 (89%)
Steroid, n (%)	5 (11%)	4 (20%)	1 (4%)
AZA/6MP, n (%)	15 (33%)	3 (15%)	12 (46%)
M, n (%)	3 (7%)	2 (10%)	1 (4%)
Previous infliximab, n (%)	19 (41%)	8 (40%)	11 (42%)
Previous adalimumab, n (%)	9 (20%)	1 (5%)	8 (31%)